Jim Webster is a member of the Investment Committee and is Duke Royalty’s Chief Investment Officer, with responsibility to oversee the due diligence and negotiations on prospective investment opportunities for the Company; direct the execution of royalty transactions approved by the Duke Royalty board; and monitor royalty investments made by the Company.
Prior to joining the Company, between 2003 and 2009, as Managing Partner and Chair of the Investment Committee for Capital Royalty Partners LLC (now CRG L.P.), Mr. Webster was instrumental in raising $325 million for the firm’s first fund. In his capacity as Chair of its Investment Committee, he led due diligence and negotiations on royalty interests for the firm. Today, CRG L.P. has approximately $2 billion under management.
Between 1993 and 2002, from virtually the inception of Drug Royalty Corporation Inc, Mr. Webster was a senior member of the world’s first public pharmaceutical based royalty company, listed on the Toronto Stock Exchange. Mr. Webster served in various capacities including President, Chief Executive Officer, and Chairman of its Investment Committee and oversaw the firm’s growth from its startup phase through to its eventual sale in 2012 for C$133m. At Drug Royalty Corporation Inc, he identified, assessed and negotiated investments in the pharmaceutical and biotechnology sectors. The company (now DRI Capital Inc) continues to be a leading royalty investor, with over $3 billion under management.
Mr. Webster holds a Masters of Business Administration from the Richard Ivey School of Business, and is also a CFA Charterholder and a Canadian Professional Accountant of Canada. He also completed the Columbia Executive Management Program in New York.